Webcast scheduled for Wednesday, February 21 at 11:30 a.m. Eastern TimeCARLSBAD, Calif., Feb. 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 21st at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2023 financial results.The live webcast may be accessed at https://ir.ionispharma.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.About Ion ...

Ionis Pharmaceuticals (IONS) announced positive top-line results from the phase III OASIS-HAE study on its investigational drug donidalorsen in patients aged 12 years and older with hereditary angioedema (HAE).The OASIS-HAE study randomized study participants into three equal groups over a 24-week treatment period — two groups evaluating an 80mg dose of donidalorsen administered once every four weeks (Q4W) and another group wherein the drug was administered once every eight weeks (Q8W). The third group admi ...

Donidalorsen met the primary endpoint with a statistically significant reduction in the rate of HAE attacks in patients treated every 4 weeks or patients treated every 8 weeks  Donidalorsen demonstrated a favorable safety and tolerability profile Ionis is preparing to submit a New Drug Application with U.S. FDA Data to be presented at an upcoming medical congress CARLSBAD, Calif., Jan. 22, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results for the Pha ...

– Numerous value-driving commercial, regulatory and pipeline milestones anticipated – CARLSBAD, Calif., Jan. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2023 achievements and previewed a number of important milestones expected in 2024. Ionis will provide a business update at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10 at 3pm PT; the presentation is available today on the Ionis website. In 2023, Ionis made sig ...

MicroStockHub Investment Overview The biotech sector of the stock market is finishing 2023 on a high after what has been a difficult couple of years. Buoyed by a Big Pharma M&A spree - the globally recognized Pharmas AbbVie (ABBV) and Bristol-Myers Squibb (BMY) have respectively spent a total of $18.8bn acquiring antibody drug conjugate ("ADC") specialist ImmunoGen (IMGN) and neuroscience pioneer Cerevel Therapeutics, and $18.1bn acquiring Karuna Therapeutics (KRTX) and its highly rated schizophrenia dr ...

U.S. FDA approval based on Phase 3 NEURO-TTRansform results showing WAINUA demonstrated consistent and sustained benefit halting neuropathy disease progression and improving neuropathy impairment and quality of life Additional regulatory reviews for WAINUA underway in rest of world WAINUA will be available in the U.S. in January 2024 CARLSBAD, Calif., Dec. 21, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ion ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2023 Earnings Conference Call November 2, 2023 11:30 AM ET Company Participants Wade Walke - Senior Vice President, Investor Relations Brett Monia - Chief Executive Officer Onaiza Cadoret - Chief Global Product Strategy & Operations Officer Richard Geary - Chief Development Officer Beth Hougen - Chief Financial Officer Eugene Schneider - Chief Clinical Development Officer Conference Call Participants Gary Nachman - Raymond James Luca Issi - RBC Capital Yale Jen - ...

On Today's Earnings Call Q3:23 Business Update and Financial Results 2 Brett Monia, Ph.D. Chief Executive Officer Beth Hougen Chief Financial Officer Eugene Schneider, M.D. Chief Clinical Development Officer Eric Swayze, Ph.D. Executive Vice President, Research IONIS Forward-Looking Statements 3 This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial potential of QALSODYTM (tofersen), SPINRAZA® (nusinersen), TEGSEDI® (inotersen), WA ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 (Exact name of Registrant as specified in its charter) Delaware 33-0336973 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 2855 Gazelle Court, Carlsbad, California 92010 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECU ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2023 Earnings Conference Call August 9, 2023 11:30 AM ET Company Participants Wade Walke - SVP, IR Brett Monia - CEO Richard Geary - Chief Development Officer Beth Hougen - CFO Onaiza Cadoret - Chief Global Product Strategy & Operations Officer Eugene Schneider - Chief Clinical Development Officer Eric Swayze - EVP, Research Conference Call Participants Myles Minter - William Blair Robert Finke - Guggenheim Partners Kostas Biliouris - BMO Capital Markets Mike Ul ...